Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib

December 1, 2030

Company: Arcus Biosciences, Inc. (RCUS)
Drug: casdatifan
Indication: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma

Other upcoming events for RCUS

Phase 2 StartPhase 2 Start: PRE-surgical NEOadjuvant Sandwich Immunotherapy With HIF inhibiTion in Renal Cell Carcinoma (PRENEOS

Patent ExpiryPatent/Exclusivity Expiry: ONMEL

Phase 3 ReadoutPhase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chem

Patent ExpiryPatent/Exclusivity Expiry: COMETRIQ

Patent ExpiryPatent/Exclusivity Expiry: STIVARGA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib — RCUS Phase 3 Readout | BioSniper